Kate Haviland

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Greg Tourangeau, as attorney-in-fact for Kate Haviland
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Kate Haviland

Form 4 holding Chief Executive Officer, Director

Blueprint Medicines Corp

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
$2,537,920
Report date
17 Jul 2025
Price
$36.05
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Bicara Therapeutics Inc.

Security class
Common Stock
Shares / value
7,437
Estimated value
$98,491
Report date
12 Sep 2024
Price
$13.24
Ownership
Direct
Form 4 holding Director

Avalyn Pharma Inc.

Security class
Stock Option (Right to Buy)
Shares / value
26,978
Estimated value
Report date
29 Apr 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Kate Haviland

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .